Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q3 EPS of ($0.16), $0.03 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $29.6 million versus the consensus estimate of $30.29 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.